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Abstract
Fractalkine (CX3CL1, FKN) is expressed in the inflamed vascular wall and absence of FKN reduces atherogenesis. Whether
FKN is expressed throughout all stages of atherosclerotic disease and whether it directly contributes to monocyte
recruitment to atherosclerotic lesions is not known. We collected human atherosclerotic plaque material and blood samples
from patients with carotid artery disease undergoing endarterectomy. Plaques were analyzed by immunohistochemistry
and qPCR. We found that FKN is expressed at all stages of atherosclerotic lesion formation, and that the number of FKN-
expressing cells positively correlates with the number of CX3CR1-positive cells in human carotid artery plaques. In the
circulation, soluble FKN levels are significantly elevated in the presence of high-grade (sub-occlusive) stenosis. To determine
the role of the FKN-CX3CR1 axis for monocyte adhesion in vivo we then performed intravital videofluorescence microscopy
of the carotid artery in ApoE2/2mice. Notably, FKN-CX3CR1 interactions are critical for recruitment of circulating monocytes
to the injured atherosclerotic vascular wall. Thus, this chemokine dyad could represent an attractive target for anti-
atherosclerotic strategies.
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Introduction
Rupture of carotid artery atherosclerotic plaque causes transient
ischemic attack and stroke. Chemokines play a central role in
atherogenesis and support the development of an unstable plaque
phenotype in manifest lesions [1,2,3]. The membrane-bound
chemokine fractalkine (CX3CL1, FKN) was detected in advanced
atherosclerotic plaques [4] [5,6]. In mouse models of atheroscle-
rosis, absence of FKN or its receptor CX3CR1 protects from
atherosclerotic lesion formation [7,8,9] and humans with a
polymorphism for CX3CR1 exhibit a decreased risk for develop-
ing coronary artery disease [10,11,12]. However, it is unknown if
FKN is expressed in early stages of lesion development and
whether FKN directly modulates leukocyte recruitment from
circulating blood in vivo. The accumulation of monocytes within
the vascular wall and the subsequent differentiation into macro-
phages/dendritic cells (DC) plays a critical role in every stage of
atherosclerotic lesion formation [13,14]. At later stages monocyte
recruitment is important for atherosclerotic plaque maintenance
[15]. CX3CR1 could contribute to this process as it mediates cell
migration and adhesion of monocytes, at least in vitro [16].
Experiments that followed atherosclerotic lesion development over
several days suggested that CX3CR1 represents an important
receptor for monocytes to accumulate in plaque in murine models
of atherosclerosis [17]. However, leukocyte subsets were thought
to enter the vascular wall primarily through the adventitia via vasa
vasorum [18,19]. Interestingly, recent data by Steinman and
colleagues described the presence of monocyte-derived DC located
in the arterial intima in healthy and atherosclerotic mouse aorta
[20]. Thus, it needs to be determined whether circulating
monocytes can actually bind directly to plaque and if CX3CR1
was involved in this process.
Finally, in advanced atherosclerotic lesions monocytes/macro-
phages contribute to plaque instability and thereby provide the
foundation for atherothrombosis [21]. Monocytes promote
thrombus formation by local exposition of potent procoagulant
mediators such as tissue factor at the site of vascular injury [22].
However, it is not understood if and how chemokines like FKN
contribute to unstable atherosclerotic disease.
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In this study we addressed the presence of FKN in the vascular
wall and of soluble FKN in blood at different stages of carotid
artery disease in humans. Unexpectedly, we found that FKN is
expressed in substantial amounts already at early stages of
atherosclerosis. In ApoE-deficient (ApoE2/2) mice we then
analyzed by real time videomonitoring acute monocyte recruit-
ment to atherosclerotic carotids showing that FKN is capable of
recruiting monocytes directly from the blood stream, and that
injury of the atherosclerotic artery strongly increases FKN-
CX3CR1-dependent monocyte adhesion. Our data substantiate
a critical role for the FKN-CX3CR1 dyad in atherosclerosis.
Materials and Methods
Recruitment of Patients
A total of 137 patients with atherosclerotic carotid artery
disease, who were referred to the Klinikum Rechts der Isar,
Technical University Munich, for carotid endarterectomy (CEA)
were studied consecutively. Patient informed and written consent
was obtained in accordance with the Ethics Committee of the
Faculty of Medicine of the Technical University Munich. The
Ethics Committee of the Faculty of Medicine of the Technical
University Munich specifically approved this study. Grade of
carotid artery stenosis was determined sonographically [23].
ELISA
Venous blood samples were taken within two days prior to
surgical intervention from the cubital vein and centrifuged after
clot formation to obtain serum samples. Soluble FKN were
measured by ELISA (R&D Systems) as described previously [24].
Immunohistochemistry
Carotid plaque specimens were processed as described previ-
ously [25]. Cross-sectional immunohistological analysis was
performed for all carotid tissue specimens and atherosclerotic
lesions were quantified according to current guidelines of the
American Heart Association (AHA) [26–27]. Antigen retrieval was
performed using heat and citrate pH 6.0 buffer. Anti-human
antibodies were directed against FKN (rabbit polyclonal, TP213,
Torrey Pines), CX3CR1 (rabbit polyclonal, TP502, Torrey Pines),
vascular smooth muscle cells (anti-SMA, Dako, Glostrup, Den-
mark), endothelial cells (anti-von Willebrand factor (factor VIII),
Dako) and macrophages (anti-CD68, Dako). Following primary
antibody incubation, von Willebrand Factor and SMA were
visualized using the APAAP ChemMate Detection Kit (rabbit anti-
mouse; Dako) according to the manufacturer’s instructions. All
other primary antibodies were detected by LSAB ChemMate
Detection Kit (biotinylated goat anti-mouse/anti-rabbit; Dako).
For immunofluorescent staining, samples were blocked with
normal goat IgG (Invitrogen) for 30 min before overnight labeling
at 4uC with primary antibodies directed against human CX3CR1
(rat IgG2b, clone 2A9-1, MBL) and FKN (rabbit polyclonal,
TP213, Torrey Pines). All antibodies were diluted in PBS
containing 0.5% BSA and 0.3% Triton X-100. Samples were
washed and incubated with Cy3-conjugated goat anti-rat (Jackson
ImmunoResearch Laboratories, Inc.) and Alexa488-conjugated
goat anti-rabbit secondary antibodies (Invitrogen), and 4,6-
diamidino-2-phenylindole (DAPI; diluted 1:400; Invitrogen) for
nuclei counter-staining. Specimens were then prepared in
mounting medium (Vector Laboratories) and visualized using a
Leica TCS SP5 confocal microscope with 206/0.5 (dry) objective.
Rat IgG2b and rabbit IgG, used as negative controls, were from
Abcam and Dako, respectively (Figure S1).
Image Analysis
Analysis for FKN and CX3CR1 distribution within plaque was
performed by using ImageJ software (release 1.46, National
Institute of Health) and Nikon NIS Elements Version 3.0 software
(NIS-Elements Advanced Research). Stained cells were labeled
and positive events were determined by histogram and pixel count.
Subsequently, the individual areas were encircled and the
automatic pixel counting of stained cells was acquired. Analysis
of FKN and CX3CR1 colocalization was performed following
immunofluorescent staining as described previously [28].
RNA Extraction from Paraffin
Quantitative analysis of FKN gene expression was performed
applying a previously described method, which was optimized for
formalin-fixed, paraffin-embeded tissues [29]. Total RNA was
isolated using the High Pure RNA Paraffin Kit (Roche). Three
20 mm sections were cut from each tissue block, and proteinase K
digestion time was 12 hours for each sample. All other steps were
performed as indicated in the manufacturer’s protocol. After total
RNA isolation, samples were stored at 280uC until use.
rtPCR
Template cDNA was synthesized from 2 mg of total RNA using
the High Capacity cDNA Archive Kit (Applied Biosystems).
Quantitative PCR analysis was performed using SYBR Green and
a GeneAmp 7700 Sequence Detection System (Applied Biosys-
tems). The human sequences of CX3CL1 were detected by
QuantiTect Primer Assays (Qiagen, Hilden, Germany) with an
amplicon length of 84 bp, which is in the optimal range for PCR
analysis of FFPE tissues [30]. Cycling conditions were 50uC for
2 min, 95uC for 15 min, followed by 40 cycles of denaturation at
95uC for 15 sec, and annealing and elongation at 60uC for 60 sec.
Gene expression ratios for each sample (regulation factors,
standard deviation) were calculated using the dCt method [31]
and normalized against beta actin. Experiments were performed
as triplicates, including non-Reverse Transcriptase and non-
template controls. Dissociation analysis confirmed the specificity
of the reaction.
Cells
Monocytes were sorted from CX3CR1GFP/+ mice using a
DAKO-Cytomation MoFlo High Speed Sorter based on expres-
sion of GFP [32]. CX3CR1-expressing lymphocyte populations
were excluded using anti-mouse CD3e (clone 145-2C11), CD19
(1D3), and NK1.1 (clone PK136) antibodies (BD Pharmingen).
The mouse monocyte cell line (WEHI 274.1) was purchased from
European Collection of Cell Cultures (Porton Down, Salisbury,
Wiltshire, UK) and maintained in suspension culture as previously
described [33].
Stable Transfection of WEHI-274.1 Cells with Sure
Silencing shRNA Plasmids
Murine monocytic cells (WEHI-274.1) were transfected with 4
different short hairpin RNA (shRNA) expressing plasmids (Sure
Silencing shRNA Plasmid for Mouse CX3CR1, SABiosciences)
validated specifically to knock down the expression of murine
CX3CR1 with a guaranteed minimized potential for non-specific
and ‘‘off-target’’ effects. Cells were selected for neomycin
resistance by G418 treatment and a pool of stably transfected
cells was generated to avoid clonal selection. Among the 4
constructs with different designs for shRNA provided by the kit,
one caused a significant knock down of the FKN receptor
expression (Figure S2). A negative control shRNA expression
Fractalkine Mediates Monocyte Recruitment
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vector included in the kit, which expressed a shRNA with limited
homology to any known sequences in the mouse genome, was used
to generate a pool of stably transfected control cells.
Flow Cytometry
CX3CR1 surface expression was assessed by flow cytometry
(Figure S2) using a rabbit anti-rat CX3CR1 antibody (rabbit
polyclonal, TP501, Torrey Pines Biolabs), which is cross reactive
to CX3CR1 of mice [34], and an anti-rabbit PE secondary
antibody (#558416, BD Pharmingen).
Mice
4-week-old male C57Bl6 ApoE2/2 (C57BL/6J-ApoEtm1Unc)
mice (The Jackson Laboratory) were fed a 0.25% cholesterol diet
(Harlan research diets, 0% cholate) for another 14 week. This
atherosclerosis model leads to formation of atherosclerotic plaque
in the carotid artery as published previously by Nakashima and
colleagues [35] as well as by our group [36,37]. Experiments were
performed using 18-week-old male animals. CX3CR1GFP/GFP
(B6.129P-CX3CR1tm1Litt/J) mice (The Jackson Laboratory) ex-
press the green fluorescence protein (GFP) under the control of the
endogenous CX3CR1 promoter [38]. Heterozygous
CX3CR1GFP/+ mice were used for experiments. All mice were
maintained in a pathogen-free environment. All experimental
procedures on animals met the requirements of the German
legislation on protection of animals and were approved by the
Government of Bavaria, Germany.
Intravital Microscopy Animal Model
Intravital microscopic studies of murine carotid arteries were
performed as previously described [37,39]. The right jugular vein
of anesthetized ApoE2/2 mice was isolated and a catheter was
inserted. 56104 murine monocytes or 56106 WEHI-274.1 cells
were injected intravenously via the jugular catheter. Endogenous
expression of GFP was sufficient for intravital microscopy of
monocytes from CX3CR1GFP/+ mice, while WEHI-274.1 were
labeled with 5-carboxyfluorescein diacetate succinimidyl ester
(DCF). Interaction of monocytes or WEHI cells with the vascular
wall of atherosclerotic carotids was visualized using a BX51W1
microscope (206water immersion objective, Olympus) equipped
with a MT20 monochromator for epi-illumination as reported
previously [37,39]. Therefore, the common carotid artery was
carefully exposed at a distance of 3 mm distal and 7 mm proximal
of the carotid bifurcation. Monocyte interaction with the vessel
wall was monitored over 30 minutes, then ligature injury was
induced and imaging was continued for another 30 minutes. To
induce carotid injury, the vessel was ligated vigorously for 5 min,
resulting in a circular incision into the endothelium and exposure
Figure 1. Immunohistochemistry of FKN and CX3CR1 in atherosclerotic lesions of human carotid arteries. Representative images of
human atherosclerotic plaque in different stages of lesion development (I–VI). Staining was performed with antibodies against FKN, CX3CR1, the
macrophage marker CD68, and a-smooth muscle actin (SMA). Bars, 200 mm. Asterisks indicate the luminal side of the vessel.
doi:10.1371/journal.pone.0043572.g001
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of the subendothelial collagen layer [40]. The ligation was
removed after 5 min. Injury of the vessel wall leads to recruitment
of circulating blood cells to the site of injury endothelial
denudation [41]. Number of adherent cells was quantified and
given as n/mm2 vessel area (n = 4–8 carotid arteries per group).
To study the role of FKN for monocyte recruitment in vivo, we pre-
treated mice with either a function blocking anti-mouse FKN
antibody (rabbit polyclonal, TP233, Torrey Pines) or rabbit IgG.
TP233 or control IgG were pre-injected 24 hrs (4 mg/kg
intraperitoneal) and 15 min (2 mg/kg intravenous) prior to
experiments [42].
Statistical Analysis
Data represent mean 6 SEM. Kolmogorov–Smirnov test was
used to assess the normal distribution of the experimental data. In
case of normal distribution the unpaired, 2-tailed t-test was
applied. For all other data the non-parametric Mann-Whitney U-
test was used. A value of P,0.05 was regarded significant. The
correlation between FKN and CX3CR1 positive cells was
performed using linear regression analysis (Prism 5 Software,
Graphpad).
Results
To systematically analyze FKN expression in atherosclerotic
plaque of human carotid arteries we obtained tissue specimen
from patients undergoing CEA. Unexpectedly, we detected FKN
at all stages of atherosclerotic lesion development using qPCR
analysis and immunohistochemistry. FKN positive staining was
found in various areas of the vascular wall (Figure 1) and
comprised macrophages, smooth muscle cells and endothelium,
including intraplaque microvessels (Figure 1, 2, S3, S4). In both
early and advanced stages of lesion development, FKN was more
prominent in deeper layers of the vessel wall (Figure 1, S5). In
advanced plaques (V–VI), we also found relative enrichment in the
plaque core region while FKN staining was less prominent in the
overlying fibrous cap (Figure 1, 2, S5). Importantly, staining for
the FKN receptor CX3CR1 closely collocated with FKN-positive
structures (Figure 1, 3). In fact, most CX3CR1 positive events
were also positive for FKN and the percentage of double-positive
cells increased from early to advanced stages (Figure 3A). Further,
we determined a positive correlation between the number of FKN-
positive and CX3CR1-positive events, which was more significant
in advanced lesions (Figure 3B). The latter finding is comparable
Figure 2. FKN positive structures in an advanced atherosclerotic lesion. Image of an advanced atherosclerotic plaque (VI) isolated by CEA
from the human carotid artery. Insets magnify FKN positive structures within the plaque (upper row). Bottom row shows consecutive stainings for
smooth muscle cells (SMA), endothelium and neovessels (Factor VIII), and macrophages (CD68). Upper scale bar: 200 mm, lower scale bar: 40 mm.
Asterisk indicates the luminal side of the vessel.
doi:10.1371/journal.pone.0043572.g002
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Figure 3. Double immunofluorescence analysis of FKN and CX3CR1 expressing cells. (A) Percent distribution of FKN (green) and CX3CR1
(red) single positive and double positive (red-green stripes) cells in early (I–III) and advanced (V–VI) plaque. n = 4 carotids per group. (B) Quantitative
analysis of the number of FKN and CX3CR1 positive cells in human carotid plaque. The correlation between the co-incidence of both markers was
calculated by linear regression analysis. Upper panel: early plaque (I–III), r = 0.44, p,0.01. Lower panel: advanced plaque (V–VI), r = 0.74, p,0.0001. (C)
A representative section from an atherosclerotic lesion (V–VI) was stained for FKN (green), CX3CR1 (red), and DAPI (blue). Bars, 100 mm. Asterisks
indicate the luminal side of the vessel.
doi:10.1371/journal.pone.0043572.g003
Figure 4. Quantitative analysis of FKN expression and FKN serum levels. (A) PCR analysis of FKN expression in atherosclerotic plaques of
different AHA stages. Graph indicates relative expression ratio as calculated from the real-time PCR efficiencies and the crossing point deviation of
FKN versus control. Mean FKN expression per gram plaque tissue did not differ significantly between AHA stages I–VI. (B) Serum levels of sFKN in 10
patients with moderate (50–69%), 83 with advanced (70–89%), and 44 with subocclusive (90–99%) carotid artery stenosis. Patients with subocclusive
stenosis showed significantly higher levels of sFKN. **p,0.001 for 50–69% vs. 90–99% (0.4460.04 ng/ml vs. 0.8860.14 ng/ml). ***p,0.0001 for 70–
89% vs. 90–99% (0.4360.02 ng/ml vs. 0.8860.14 ng/ml). p = ns for 50–69% vs. 70–89%.
doi:10.1371/journal.pone.0043572.g004
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to previous reports by Lucas and colleagues on patients with
coronary artery atherosclerosis [28].
To quantify FKN expression within plaque we next performed
PCR analysis of plaque specimens. In line with the findings
obtained by immunohistochemistry, FKN was expressed through-
out all stages of atherosclerotic disease (Figure 4A). High amounts
of FKN were expressed already at early stages of lesion
development. However, mean amounts of CX3CL1 per gram
plaque tissue were not statistically different in-between groups
(Figure 4A). On inflamed endothelium and within the vascular
wall, FKN is expressed as a transmembranous molecule. However,
the chemokine domain can be cleaved from the cell surface to
produce a soluble chemoattractant [43]. Elevated levels of soluble
FKN (sCX3CL1, sFKN) have been described in chronic
inflammatory disease in humans and in patients with acute
coronary syndrome [5]. Thus, we next assessed whether levels of
circulating sFKN are associated with the degree of carotid artery
stenosis. Patients with moderate (50–70% stenosis) and advanced
(70–90% stenosis) carotid artery disease showed similar levels of
circulating sFKN. However, patients with carotid artery stenosis
near occlusion (90–99% stenosis) showed significantly elevated
levels of sFKN (Figure 4B). Importantly, patient characteristics
were well balanced between the groups and did not differ
significantly in terms of sex, age, risk factors and medication
(Table S1).
FKN and its receptor CX3CR1 play an important role in
atheroprogression [7,8,9]. In vitro, membrane-bound FKN medi-
ates adhesion of leukocyte subsets [16,44]. However, whether the
FKN-CX3CR1 axis is involved in the direct recruitment of
circulating monocytes to the atherosclerotic vascular wall in vivo is
not known. To address this question, we first isolated murine
monocytes from CX3CR1GFP/+ mice and injected 56104 cells
intravenously into 18-week-old ApoE2/2 mice. We then studied
monocyte adhesion at the carotid artery by intravital microscopy.
Importantly, we directly observed the recruitment of monocytes to
atherosclerotic endothelium, although total events were relatively
low within 1 hour of microscopy (Figure 5A). However, when we
mechanically injured the atherosclerotic artery, a significant
increase in adherent CX3CR1GFP/+ monocytes was observed
(Figure 5A). As FKN is relevantly expressed in atherosclerotic
arteries, the findings provoked us to further analyze the role of
FKN in the process of monocyte recruitment to atherosclerotic
lesions. To increase the number of adhesion events we next used
cultured murine monocytes (WEHI-274.1) and injected 56106
cells into ApoE2/2 mice. As observed with GFP+ monocytes
(Figure 5A), adhesion of WEHI cells also increased strongly
following injury (Figure 5B). Importantly, pretreatment with a
neutralizing antibody diminished WEHI recruitment
(Figure 6A,B). Thus, FKN expressed within atherosclerotic lesions
is an important mediator for the recruitment of circulating blood
monocytes.
Whether FKN mediates monocyte adhesion directly via
CX3CR1 is not known. Early work suggested that FKN
interactions with CX3CR1 should be strong enough to mediate
firm adhesion under conditions of high wall shear stress [45]. To
test whether FKN and CX3CR1 are both involved in monocyte
recruitment in vivo, we next injected WEHI cells into ApoE2/2
after silencing of CX3CR1. shRNA-treatment significantly
reduced WEHI-247.1 recruitment to the injured carotid artery.
Unexpectedly, additional pre-incubation with FKN antibody did
not further affect the adhesion of shRNA-treated WEHI-274.1
cells (Figure 6C), suggesting that the reduction observed was
mediated primarily by FKN-CX3CR1 interaction. Thus, our
findings suggest a critical role of the FKN-CX3CR1 axis for
monocyte recruitment to the injured vessel wall in this mouse
model of accelerated atherosclerosis.
Discussion
FKN plays an important role in atherosclerotic vascular disease.
Although some progress has been made in recent years to better
understand the role of this chemokine in atherosclerosis and the
mechanisms underlying monocyte recruitment, some issues
remained elusive. For example, it was unknown at which stage
of disease FKN becomes expressed and whether levels of
circulating sFKN may reflect increased FKN expression within
the vascular wall. While FKN is not detectable in the vessel wall of
healthy mice [46] and human subjects [6], it has been described in
advanced atherosclerotic lesions in different vascular beds [4].
Using immunohistochemistry and real-time PCR we show here
Figure 5. Monocyte and WEHI 274.1 recruitment to intact and injured atherosclerotic carotid artery lesions. (A) Monocyte adhesion to
atherosclerotic endothelium (indicated ‘before injury’) and to the injured atherosclerotic vascular wall (indicated ‘after injury’) in ApoE2/2 mice (B)
WEHI 274.1 adhesion to inflamed atherosclerotic endothelium and to the injured atherosclerotic vascular wall in ApoE2/2 mice. Adhesion of
monocytes and WEHI 274.1 was significantly increased following injury. n = 4–8, *p,0.05, **p,0.001.
doi:10.1371/journal.pone.0043572.g005
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that FKN is substantially expressed already at very early stages of
atherosclerosis. This suggests a role of this chemokine in the initial
stages of lesion development in addition to its relevance in
advanced disease. Interestingly, FKN positive staining was
detected among others on endothelium of atherosclerotic carotid
arteries. This finding was not observed in previous studies on
human atherosclerosis [6,28], but it is in line with FKN expression
analysis in atherosclerotic endothelium of ApoE2/2 mice [8].
Leukocytes play a critical role in atherosclerosis. While
leukocyte subsets reside within the normal vascular wall, their
number strongly increases with the onset of atherogenesis [19]. In
addition to constitutive leukocyte surveillance and trafficking,
monocytes and lymphocytes are then specifically recruited in
larger amounts to the site of lesion formation. This process is
controlled by distinct signals that mediate their migration and
adhesion. It involves eg. L-selectin and CXCR6, the only known
receptor to the membrane-bound chemokine CXCL16 [18].
There is also evidence pointing to a role of CX3CR1 for monocyte
recruitment into plaque [17]. Membrane-bound FKN mediates
migration of immune cells and smooth muscle cells during
atherogenesis [9,28]. In line with these studies, we found that
the number of CX3CR1-positive cells in carotid artery lesions
increased in the course of atherogenesis and correlated signifi-
cantly with the presence of FKN-positive structures. However,
monocytes are thought to accumulate within the vascular wall
entering primarily through the vasa vasorum located in the
adventitia [18,19]. Using intravital microscopy we show here that
blood-borne monocytes can also be directly recruited to the
luminal side of the vessel wall. We found that both isolated murine
monocytes as well as cultured monocytes (WEHI 274.1) adhered
to atherosclerotic endothelium and injury of carotid artery plaque
strongly increased monocyte adhesion. This process was mediated
predominantly by FKN and pretreatment with a neutralizing anti-
FKN antibody diminished monocyte recruitment. Our findings
not only highlight the pathophysiological relevance of FKN in
CAD, but we here identified a mechanism by which monocyte-
dependent macrophages/DC might accumulate within the arterial
intima.
Figure 6. FKN and CX3CR1 mediate WEHI 274.1 recruitment to injured atherosclerotic carotid arteries. (A) WEHI 274.1 adhesion to
mechanically injured atherosclerotic carotids was studied over 30 minutes in the presence of an IgG control antibody (black bars) or a function
blocking anti-FKN antibody (white bars). (B) Representative intravital microscopic images from mouse carotid arteries at baseline (left) and
15 minutes (right) after injury of the atherosclerotic vascular wall, pretreated with either an anti-FKN antibody (upper row) or an isotype IgG control
antibody (lower row). WEHI 274.1 cells were stained with DCF (green). Bars, 50 mm. n= 4–8, *p,0.05, **p,0.01. (C) WEHI 274.1 adhesion is dependent
on FKN-CX3CR1 interactions. WEHI 274.1 were transfected with shRNA-encoding plasmids to silence CX3CR1 expression (grey and white bars) or
transfected with a plasmid encoding a scrambled control shRNA (black bars). Prior to transfusion the animals were pretreated either with a rabbit IgG
control antibody (grey bars) or a function blocking anti-FKN antibody (white bars). WEHI 274.1 adhesion to injured atherosclerotic carotids was
analyzed over 30 minutes.
doi:10.1371/journal.pone.0043572.g006
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Initial work on FKN suggested that its interactions with
CX3CR1 are strong enough to mediate firm adhesion under
conditions of high wall shear stress [45]. However, flow
experiments in vitro indicated that FKN only effectively mediated
leukocyte adhesion in the presence of another adhesion molecule,
like VCAM-1 or P-selectin, that supports capture and rolling
before FKN is capable of mediating firm adhesion [44,47,48]. As
determined in the present study FKN-mediated monocyte binding
in vivo involves predominantly its receptor CX3CR1. Thus, this
interaction seems sufficient for monocyte recruitment in vivo. A
possible explanation for this finding is that the cumulative density
of FKN within advanced atherosclerotic lesions is higher than on
inflamed endothelium in vitro. However, involvement of other
adhesion molecules cannot be excluded in this model.
It is tempting to speculate that by recruiting monocytes to the
injured atherosclerotic plaque FKN-CX3CR1 might contribute to
plaque vulnerability and rupture, which may lead to athero-
thrombosis and stroke as one major clinical sequela. Indeed,
locally recruited monocytes foster arterial thrombosis for example
by release of tissue factor-bearing microparticles [22,49].
In addition to its’ existence as a membrane-bound molecule,
soluble FKN also seems to be of pathophysiological relevance.
Membrane-bound FKN is cleaved by metallopeptidases, eg.
ADAM 10 and ADAM 17 [43], and serves as a chemoattractant
for different leukocyte subsets [13]. Circulating sFKN can be
detected in blood of patients with various inflammatory diseases as
well as healthy subjects [5,13,50]. We found that sFKN blood
levels are similar in patients with moderate and advanced carotid
artery stenosis. Interestingly, values are well comparable to sFKN
levels in patients with stable coronary artery disease [5]. However,
severe stenosis leading to subtotal occlusion of the carotid artery
significantly increased sFKN levels in circulating blood. In
contrast, expression of the chemokine within the vascular wall
can already be detected at early stages of carotid artery disease.
Given our findings and the previous data on patients with
coronary artery disease we believe that sFKN is not suitable as a
biomarker for patients with atherosclerosis per se, but might be
useful to identify patients with unstable disease.
In conclusion, our findings suggest that FKN and CX3CR1
could represent an interesting therapeutic target in patients with
atherosclerotic vascular disease. This seems especially relevant in
the context of CX3CR1 antagonists being engineered for
treatment in humans [51].
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